• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有或不伴有供者特异性抗体的慢性活动性抗体介导的排斥反应具有相似的组织形态学和临床结局:一项回顾性研究。

Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study.

机构信息

Department of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

出版信息

Transpl Int. 2018 Aug;31(8):900-908. doi: 10.1111/tri.13154. Epub 2018 Apr 16.

DOI:10.1111/tri.13154
PMID:29570868
Abstract

Chronic-active antibody-mediated rejection (c-aABMR) is defined as histological evidence of chronic endothelial injury (cg), also known as transplant glomerulopathy, and either microvascular inflammation (MVI) or positivity for C4d. Importantly, the presence of donor-specific antibodies (DSA) is currently still mandatory for the diagnosis of c-aABMR. This retrospective study of 41 c-aABMR patients investigates whether cases suspicious for c-aABMR (DSA negative, n = 24) differ from cases of c-aABMR (DSA positive, n = 17) with respect to renal histology, allograft function and long-term graft survival. All included patients had progressive loss of allograft function and were diagnosed by for cause biopsy and scored according to the Banff '15 criteria. In all DSApos cases, DSA were de novo and the majority was directed against HLA-II being mostly anti-HLA-DQ antibodies. There were no statistically significant differences in clinical characteristics, decline in allograft function and renal allograft survival in cases with or without DSAs. All cases showed chronic histomorphological damage and inflammation, irrespective of the presence of DSA. Renal histology and clinical outcome of patients suspicious for c-aABMR (DSAneg) do not significantly differ from patients with a diagnosis of c-aABMR (DSApos). We believe that our study adds to the ongoing debate regarding the need for DSAs to be present for the diagnosis of c-aABMR.

摘要

慢性活动性抗体介导的排斥反应 (c-aABMR) 定义为慢性内皮损伤 (cg) 的组织学证据,也称为移植肾小球病,以及微血管炎症 (MVI) 或 C4d 阳性。重要的是,目前供体特异性抗体 (DSA) 的存在仍然是诊断 c-aABMR 的必要条件。本研究回顾性分析了 41 例 c-aABMR 患者,探讨了疑似 c-aABMR(DSA 阴性,n = 24)病例与 c-aABMR(DSA 阳性,n = 17)病例在肾组织学、同种异体移植物功能和长期移植物存活率方面是否存在差异。所有纳入的患者均有进行性同种异体移植物功能丧失,并通过因病因活检诊断,并根据 Banff '15 标准进行评分。在所有 DSApos 病例中,DSA 均为新出现的,且大多数针对 HLA-II,主要为抗 HLA-DQ 抗体。有无 DSA 的情况下,临床特征、同种异体移植物功能下降和肾移植存活率均无统计学差异。所有病例均表现出慢性组织形态学损伤和炎症,无论是否存在 DSA。疑似 c-aABMR(DSAneg)患者的肾组织学和临床结局与确诊为 c-aABMR(DSApos)患者无显著差异。我们认为,我们的研究增加了关于诊断 c-aABMR 时是否需要存在 DSA 的持续争论。

相似文献

1
Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study.伴有或不伴有供者特异性抗体的慢性活动性抗体介导的排斥反应具有相似的组织形态学和临床结局:一项回顾性研究。
Transpl Int. 2018 Aug;31(8):900-908. doi: 10.1111/tri.13154. Epub 2018 Apr 16.
2
Clinical and Pathologic Feature of Patients With Early Versus Late Active Antibody-Mediated Rejection After Kidney Transplantation: A Single-Center Experience.肾移植后早期与晚期主动抗体介导排斥反应患者的临床与病理特征:单中心经验。
Transplant Proc. 2021 Apr;53(3):1025-1031. doi: 10.1016/j.transproceed.2020.11.004. Epub 2021 Jan 5.
3
Clinical and pathological analyses of transplant glomerulopathy cases.移植肾肾小球病的临床与病理分析。
Nephrology (Carlton). 2014 Jun;19 Suppl 3:21-6. doi: 10.1111/nep.12243.
4
Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.循环供体特异性抗 HLA 抗体是导致移植物早期和加速纤维化的主要因素。
Kidney Int. 2017 Sep;92(3):729-742. doi: 10.1016/j.kint.2017.03.033. Epub 2017 May 26.
5
Clinicopathological Analysis of Acute/Active Antibody-Mediated Rejection in Renal Allografts According to the Banff 2013 Classification.根据 2013 年 Banff 分类的肾移植急性/活跃抗体介导排斥反应的临床病理分析。
Nephron. 2020;144 Suppl 1(Suppl 1):18-27. doi: 10.1159/000512143. Epub 2020 Dec 2.
6
Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.HLA-DQ抗体在肾移植受者慢性抗体介导性排斥反应及移植肾失功发生中的临床意义
Medicine (Baltimore). 2016 Mar;95(11):e3094. doi: 10.1097/MD.0000000000003094.
7
Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome.肾移植活检中C4d染色、供体特异性HLA抗体产生与移植肾结局之间的关联。
Transplantation. 2007 Feb 27;83(4):398-403. doi: 10.1097/01.tp.0000251430.11723.b6.
8
Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection.患者内他克莫司变异性与慢性活跃抗体介导的排斥反应无关。
PLoS One. 2018 May 10;13(5):e0196552. doi: 10.1371/journal.pone.0196552. eCollection 2018.
9
Early versus late acute antibody-mediated rejection in renal transplant recipients.肾移植受者的早期与晚期急性抗体介导的排斥反应。
Transplantation. 2013 Jul 15;96(1):79-84. doi: 10.1097/TP.0b013e31829434d4.
10
Higher Donor Age and Severe Microvascular Inflammation Are Risk Factors for Chronic Rejection After Treatment of Active Antibody-Mediated Rejection.供者年龄较高和严重的微血管炎症是治疗活动性抗体介导排斥反应后慢性排斥反应的危险因素。
Transpl Int. 2024 Feb 2;37:11960. doi: 10.3389/ti.2024.11960. eCollection 2024.

引用本文的文献

1
Sensitization in Transplantation Assessment of Risk 2025 innate working group: The potential role of innate allorecognition in kidney allograft damage.2025年移植风险评估中的固有免疫工作组:固有同种异体识别在肾移植损伤中的潜在作用。
Am J Transplant. 2025 Jul 5. doi: 10.1016/j.ajt.2025.06.030.
2
Absence of IL-6 Receptor Blockade Effect on the Outcomes of Transplant Glomerulopathy in the Absence of Anti-HLA Donor-specific Antibodies.在无抗人白细胞抗原(HLA)供者特异性抗体情况下,白细胞介素-6受体阻断对移植性肾小球病结局无影响。
Transplant Direct. 2024 May 16;10(6):e1638. doi: 10.1097/TXD.0000000000001638. eCollection 2024 Jun.
3
Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe.
欧洲肾移植患者移植后慢性活动性抗体介导排斥反应的监测和管理。
Transpl Int. 2023 Jul 17;36:11381. doi: 10.3389/ti.2023.11381. eCollection 2023.
4
Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots.降低老年肾移植受者的维持性免疫抑制;连接免疫学与临床要点。
Front Med (Lausanne). 2023 Jul 12;10:1215167. doi: 10.3389/fmed.2023.1215167. eCollection 2023.
5
MHC Tetramers Specifically Identify High- and Low-avidity Donor-specific B Cells in Transplantation Tolerance and Rejection.MHC 四聚体特异性鉴定移植耐受和排斥反应中的高亲和性和低亲和性供体特异性 B 细胞。
Transplantation. 2023 Dec 1;107(12):2526-2532. doi: 10.1097/TP.0000000000004702. Epub 2023 Nov 22.
6
Pathophysiology of Rejection in Kidney Transplantation.肾移植排斥反应的病理生理学
J Clin Med. 2023 Jun 19;12(12):4130. doi: 10.3390/jcm12124130.
7
Antibody-Mediated Rejection in Kidney Transplantation: A Retrospective Study on the Impact of Donor-Specific Antibodies and on the Timing of Diagnosis.肾移植中抗体介导的排斥反应:关于供体特异性抗体影响及诊断时机的回顾性研究
Cureus. 2022 Oct 14;14(10):e30296. doi: 10.7759/cureus.30296. eCollection 2022 Oct.
8
A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection.基于班夫的组织学慢性指数与肾移植和抗体介导排斥反应患者的移植物丢失相关。
Kidney Int. 2023 Jan;103(1):187-195. doi: 10.1016/j.kint.2022.09.030. Epub 2022 Nov 1.
9
Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.用于肾脏移植临床试验终点的抗体介导排斥反应的定义建议。
Transpl Int. 2022 May 20;35:10140. doi: 10.3389/ti.2022.10140. eCollection 2022.
10
Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms.移植肾的微血管炎症:对潜在机制的再评估。
Front Immunol. 2022 Mar 22;13:864730. doi: 10.3389/fimmu.2022.864730. eCollection 2022.